European journal of gastroenterology & hepatology · 2026
Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsukimoto Mone, Fujiwara Naoto, Ito Takanori, Imai Kenji, Ariga Mizuki, Suzuki Takaya, Yamamoto Takafumi, Kawachi Mizuki, Yoshida Yuki, Owa Hirono, Tamai Yasuyuki, Shigefuku Ryuta, Tameda Masahiko, Ogura Suguru, Tanaka Hideaki, Igura Kazumasa, Imai Yasuhito, Takai Koji, Shimizu Masahito, Honda Takashi, Kawashima Hiroki, Kuzuya Teiji, Nakagawa Hayato
Аннотация
AIM: To clarify the optimal sequencing strategy of systemic therapies for unresectable hepatocellular carcinoma that maximizes efficacy and patient outcomes.
METHODS: We established a multicenter retrospective Tokai Post ICI Sequential Therapy Registry cohort across four Tertiary-Care Hospitals in Japan, enrolling patients who received first-line immune checkpoint inhibitor (ICI)-based therapy between October 2020 and May 2025. Tumor response was assessed every 2-3 months by Response Evaluation Criteria in Solid Tumors version1.1 as the primary outcome. Logistic regression models evaluated predictors of response with hospital-level mixed effects.
RESULTS: A total of 368 patients were included [median age 74 years (interquartile range: 68-80 years); 303 (82%) male]; 307 (83.4%) received atezolizumab plus bevacizumab and 61 (16.6%) durvalumab plus tremelimumab. Following discontinuation, 151 (47.0%) proceeded to second-line therapy, predominantly lenvatinib ( n = 124, 82%). Second-line lenvatinib achieved objective response rates of 12-25% and disease control rates (DCRs) exceeding 60%, independent of prior ICI regimen or response. Of 56 patients receiving third-line therapy, the sequences of atezolizumab plus bevacizumab-lenvatinib-durvalumab plus tremelimumab and durvalumab plus tremelimumab-lenvatinib-atezolizumab plus bevacizumab ( n = 19, 28.6%) demonstrated significantly higher DCR compared with other sequences (52.6 vs. 29.7%) despite comparable liver function reserve and tumor burden. In addition, durvalumab plus tremelimumab following atezolizumab plus bevacizumab-lenvatinib showed numerically higher DCR compared with durvalumab plus tremelimumab directly after atezolizumab plus bevacizumab (53.3 vs. 29.4%).
CONCLUSION: Consistent efficacy of second-line lenvatinib and favorable outcomes with ICI-lenvatinib-ICI sequences may underscore the clinical importance of therapy sequencing in advanced hepatocellular carcinoma, warranting prospective evaluation of optimal strategies.
METHODS: We established a multicenter retrospective Tokai Post ICI Sequential Therapy Registry cohort across four Tertiary-Care Hospitals in Japan, enrolling patients who received first-line immune checkpoint inhibitor (ICI)-based therapy between October 2020 and May 2025. Tumor response was assessed every 2-3 months by Response Evaluation Criteria in Solid Tumors version1.1 as the primary outcome. Logistic regression models evaluated predictors of response with hospital-level mixed effects.
RESULTS: A total of 368 patients were included [median age 74 years (interquartile range: 68-80 years); 303 (82%) male]; 307 (83.4%) received atezolizumab plus bevacizumab and 61 (16.6%) durvalumab plus tremelimumab. Following discontinuation, 151 (47.0%) proceeded to second-line therapy, predominantly lenvatinib ( n = 124, 82%). Second-line lenvatinib achieved objective response rates of 12-25% and disease control rates (DCRs) exceeding 60%, independent of prior ICI regimen or response. Of 56 patients receiving third-line therapy, the sequences of atezolizumab plus bevacizumab-lenvatinib-durvalumab plus tremelimumab and durvalumab plus tremelimumab-lenvatinib-atezolizumab plus bevacizumab ( n = 19, 28.6%) demonstrated significantly higher DCR compared with other sequences (52.6 vs. 29.7%) despite comparable liver function reserve and tumor burden. In addition, durvalumab plus tremelimumab following atezolizumab plus bevacizumab-lenvatinib showed numerically higher DCR compared with durvalumab plus tremelimumab directly after atezolizumab plus bevacizumab (53.3 vs. 29.4%).
CONCLUSION: Consistent efficacy of second-line lenvatinib and favorable outcomes with ICI-lenvatinib-ICI sequences may underscore the clinical importance of therapy sequencing in advanced hepatocellular carcinoma, warranting prospective evaluation of optimal strategies.
Предметные рубрики MeSH
AgedAged, 80 and overFemaleHumansMaleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularImmune Checkpoint InhibitorsJapanLiver NeoplasmsPhenylurea CompoundsQuinolinesRegistriesRetrospective StudiesTreatment Outcome